All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Mutation testing in AML:
What you need to know
with Charles Craddock, Ralph Hills, and Gail Roboz
Wednesday, April 23, 2025
17:30-18:30 BST
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through a grant from Bristol Myers Squibb and Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What do real-world data tell us about outcomes with venetoclax/HMA vs 7+3 chemotherapy?
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Andrew Matthews, University of Pennsylvania, Philadelphia, US. We asked, What do real-world data tell us about outcomes with venetoclax/hypomethylating agents (HMA) vs 7+3 chemotherapy?
What do real-world data tell us about outcomes with venetoclax/HMA vs 7+3 chemotherapy?
Matthews discusses a national, multicenter, retrospective study comparing venetoclax/HMA and 7+3 chemotherapy in patients aged 60–75 years, newly diagnosed with AML, and without major heart failure or chronic kidney disease, spanning all risk groups and mutational profiles. Matthews outlines the differences in baseline characteristics between the two treatment groups and highlights that although adverse events were more common in patients who received intensive chemotherapy, overall survival was significantly longer compared with those who received venetoclax/HMA.
Your opinion matters
2 votes - 23 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox